Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.”In the company’s words, NCT06160752 on ClinicalTrials.gov
- Tested for
- Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.”In the company’s words, NCT06160752 on ClinicalTrials.gov
Other drugs for Intrahepatic Cholangiocarcinoma
- FutibatinibTaiho · Phase 2/3
- TinengotinibTransThera Sciences (Nanjing), Inc. · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
Coming up1
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Mar 2027 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026